Iovance Biotherapeutics, Inc. has announced updated results from its Phase 2 IOV-LUN-202 trial for lifileucel, a treatment aimed at non-squamous metastatic non-small-cell lung cancer (mNSCLC). The company reported a 24.6% objective response rate (ORR) among 69 patients, consistent with previous results. This update is significant as it supports a planned supplemental biologics license application (sBLA) for lifileucel in 2027.

The IOV-LUN-202 trial is crucial for Iovance as it seeks to establish lifileucel as a viable treatment option for patients who have previously undergone chemotherapy and immune checkpoint inhibitor therapy. The updated findings were disclosed in a press release on October 29, 2026, highlighting the company's ongoing commitment to developing innovative cancer therapies.

Background

IOVANCE BIOTHERAPEUTICS, INC. is a biotechnology company focused on developing and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). Iovance trades on the Nasdaq under the ticker symbol IOVA.

What the Filing Says

According to the recent SEC filing (accession number 0001104659-26-120261), Iovance reported, "On October 29, 2026, Iovance Biotherapeutics, Inc. issued a press release announcing updated results from Cohorts 1 and 2 of the Company’s Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer." The full press release is attached as Exhibit 99.1.

Impact

The updated trial results may significantly influence patients suffering from non-squamous mNSCLC, as they indicate a potential new treatment pathway. The findings could also impact healthcare providers and oncologists who are exploring innovative therapies for lung cancer. Additionally, the results may affect Iovance's competitive stance within the biopharmaceutical industry, particularly among companies developing biological products.

What's Next

The filing indicates that Iovance plans to submit a supplemental biologics license application for lifileucel in 2027. Further updates on the broader population program are expected in the same year, as discussions with the U.S. Food and Drug Administration (FDA) are ongoing.